- Home
- DCTH vs BGT Comparison
DCTH vs BGT Comparison
Compare DCTH & BGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- BGT
- Stock Information
- Founded
- DCTH 1988
- BGT 2004
- Country
- DCTH United States
- BGT United States
- Employees
- DCTH N/A
- BGT N/A
- Industry
- DCTH Medical/Dental Instruments
- BGT Trusts Except Educational Religious and Charitable
- Sector
- DCTH Health Care
- BGT Finance
- Exchange
- DCTH Nasdaq
- BGT Nasdaq
- Market Cap
- DCTH 388.3M
- BGT 320.3M
- IPO Year
- DCTH N/A
- BGT N/A
- Fundamental
- Price
- DCTH $9.83
- BGT $11.88
- Analyst Decision
- DCTH Strong Buy
- BGT
- Analyst Count
- DCTH 4
- BGT 0
- Target Price
- DCTH $24.25
- BGT N/A
- AVG Volume (30 Days)
- DCTH 1.1M
- BGT 107.2K
- Earning Date
- DCTH 11-04-2025
- BGT 01-01-0001
- Dividend Yield
- DCTH N/A
- BGT 10.77%
- EPS Growth
- DCTH N/A
- BGT N/A
- EPS
- DCTH 0.06
- BGT N/A
- Revenue
- DCTH $70,240,000.00
- BGT N/A
- Revenue This Year
- DCTH $146.50
- BGT N/A
- Revenue Next Year
- DCTH $37.19
- BGT N/A
- P/E Ratio
- DCTH $175.70
- BGT N/A
- Revenue Growth
- DCTH 491.35
- BGT N/A
- 52 Week Low
- DCTH $8.87
- BGT $10.89
- 52 Week High
- DCTH $18.23
- BGT $13.42
- Technical
- Relative Strength Index (RSI)
- DCTH 40.06
- BGT 44.75
- Support Level
- DCTH $9.15
- BGT $11.73
- Resistance Level
- DCTH $12.70
- BGT $11.94
- Average True Range (ATR)
- DCTH 0.73
- BGT 0.15
- MACD
- DCTH -0.17
- BGT 0.01
- Stochastic Oscillator
- DCTH 19.16
- BGT 52.17
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
About BGT BlackRock Floating Rate Income Trust
Blackrock Floating Rate Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income. The company's secondary investment objective is to seek the preservation of capital. The Trust seeks to achieve its investment objectives by investing mainly, under normal conditions, at least 80% of its assets in floating and variable rate instruments of U.S. and non-U.S. issuers, including a substantial portion of its assets in floating and variable rate securities including senior secured floating rate loans made to corporate and other business entities.